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Abstract
Recent observations indicate that human milk oligosaccharides (HMO) are involved in a variety of physiological processes in infants. Their
metabolic fate, however, is virtually unknown. We investigated metabolic aspects in infants after endogenous 13C-labelling of HMO. An oral
bolus of natural and 13C-labelled galactose (Gal; 23 g Gal þ 4 g 13C-Gal) was given to ten lactating women. Aliquots of milk at each nursing
as well as breath samples from the mothers and urine from their infants were collected over 36 h. The 13C-enrichment of HMO and their
renal excretion was determined by isotope ratio-MS; characterisation was achieved by fast atom bombardment-MS. After the Gal bolus was
given, an immediate 13C-enrichment in milk and in infants’ urine was observed which lasted 36 h. Mass spectrometric analysis of
13C-enriched urinary fractions confirmed the excretion of a variety of neutral and acidic HMO without metabolic modification of their struc-
tures. Components with glucose split off at the reducing end were also detectable. Quantitative data regarding the infants’ intake of lacto-N-
tetraose and its monofucosylated derivative lacto-N-fucopentaose II ranged from 50 to 160 mg with each suckling, respectively; renal
excretion of both components varied between 1 and 3 mg/d. Since the intake of individual HMO by the infants was in the range of several
hundred mg per suckling, i.e. several g/d, and some of these components were excreted in mg amounts as intact HMO with the infants’
urine, not only local but also systemic effects might be expected.
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Human milk contains a large variety of complex oligosac-
charides in concentrations ranging from 10 to 20 g/l(1,2). The
quantity of these components does not only depend on
the lactational stage of the mother but is also affected by the
expression of specific glycosyltransferases in the mammary
gland(1–3). Genes encoding for H and Lewis a or x antigens
as well as the secretor status determine the presence of
a1,2-, a1,3- and/or a1,4-fucosylated core structures of oligo-
saccharides. In addition, different patterns of sialylation, i.e.
the attachment of a2,3- and/or a2,6-linked N-acetylneurami-
nic acid (NeuAc), increase the variability of human milk oligo-
saccharide (HMO) to a number of about 115 structures
characterised so far(4,5). The biological significance of HMO
for the infant, however, has not been proven yet. Since the
1950s, HMO have been thought to be growth-promoting
factors for the so-called ‘bifidus flora’ in the gut of
breastfed infants(6). Recently, the analysis of the genome of
Bifidobacteria indicated their evolutionary adaptation to
preferentially use specific milk components, particularly
HMO as their substrate(7,8). However, the bifidogenic effect
of HMO themselves and their direct impact on the intestinal
microbiota are difficult to demonstrate in vivo. The same
applies to other specific in vitro functions of HMO, such as
their potential to influence inflammatory and infectious
processes via inhibition of the attachment of pathogens to epi-
thelial cells or leucocyte endothelial and neutrophil platelet
interactions(9–12). Animal and preclinical studies indicate that
oligosaccharides like those in human milk may play an
important role in many physiological processes such as
influencing cell recognition and cell signalling, cell adhesion,
the composition of the microbiota or even affecting neuro-
development(13–15).
To better understand the underlying mechanisms, more
information regarding the metabolic fate of HMO in the infants
*Corresponding author: Professor C. Kunz, fax þ49 641 9939049, email clemens.kunz@ernaehrung.uni-giessen.de
Abbreviations: FAB-MS, fast atom bombardment-MS; Gal, galactose; HMO, human milk oligosaccharides; HPAEC-PAD, high pH anion exchange
chromatography with pulsed amperometric detection; IR-MS, isotope ratio-MS; LNFP II, lacto-N-fucopentaose II; LNT, lacto-N-tetraose; NeuAc,
N-acetylneuraminic acid; NeuAcLac, N-acetylneuraminyl-lactose; PDB, Pee Dee Belemnite.
British Journal of Nutrition (2012), 107, 957–963 doi:10.1017/S0007114511004016
q The Authors 2011
B
ri
ti
sh
Jo
u
rn
al
o
f
N
u
tr
it
io
n
is needed. In a previous study(16), we demonstrated that the
application of stable isotopes to lactating mothers leads to
the preferential incorporation of 13C-galactose (Gal) into
lactose and milk oligosaccharides. The 13C-enrichment of
HMO in this pilot study was high enough to investigate the
metabolic fate of HMO in the infants. In an earlier study, we
showed in one mother and her infant that the combination
of fast atom bombardment-MS (FAB-MS) and isotope ratio-
MS (IR-MS) is suitable to address specific questions with
regard to the metabolism of HMO in humans(17). In the pre-
sent study, we report the renal excretion of intact and partly
degraded complex oligosaccharides in ten infants after
in vivo labelling of HMO by administering 13C-Gal to their
mothers.
Subjects and methods
Subjects and study design
Exclusively breastfeeding women (n 10; 3–6 months post-
partum) participated in the present study. Three mothers
had already participated in our previous study(16) and seven
were newly recruited. Some dietary restrictions, i.e. the avoid-
ance of naturally 13C-rich foodstuffs (e.g. corn, pineapple,
fish), were given. The mothers were asked not to drink
any milk for breakfast on the study day and to record their
daily food intake during the study period. This study
was conducted according to the guidelines laid down in the
Declaration of Helsinki and all procedures involving human
subjects were approved by the ethics committee of the Univer-
sity of Giessen. Written informed consent was obtained from
all subjects/patients.
Between 08.00 and 09.30 hours, immediately after breakfast,
mothers orally ingested a Gal bolus consisting of 23 g
Gal þ 4 g 13C-Gal dissolved in about 50 ml of drinking water.
The purity of 13C-Gal (D-Gal; 1-13C) from Eurisotop (Saint-
Aubin Cedex, France) was determined to be higher than 99 %.
Milk and breath sampling of the women
A milk sample (5–10 ml) was collected immediately before
the Gal bolus was given (baseline value) and at the beginning
of each nursing during the following 36 h(16). At the same
time, mothers took breath samples and collected their urine
in 3–4 h fractions.
Sampling of the infants’ urine
For urinary collections, diapers consisting purely of cellulose
and free of other absorptive material (Procter & Gamble,
Frankfurt, Germany) were used. Urine was collected in
adhesive bags which were emptied or replaced before each
nursing. Diapers were changed before each nursing and
immediately frozen at 2208C. For urine extraction, diapers
were thawed and mechanically pressed leading to urine
yields of about 70–80 %. In previous experiments, it was
verified that the urine collection via diapers and adhesive
urine bags did not affect HMO analysis.
Separation of milk fractions and characterisation of milk
carbohydrates
The separation of whole milk into fractions with fat, proteins
and carbohydrates followed by the removal of lactose was
achieved by ultracentrifugation, acetone treatment and gel fil-
tration chromatography of the carbohydrate fraction as described
earlier(18). Then, neutral and acidic HMO were characterised
by chromatography and MS (see the following subsections).
High pH anion exchange chromatography with pulsed
amperometric detection
High pH anion exchange chromatography with pulsed
amperometric detection (HPAEC-PAD) on a Carbo Pac PA-1
column (250 £ 4·6 mm inner diameter) equipped with a
guard column and a Model PAD 2 detector (Dionex, Sunny-
vale, CA, USA) were used for characterisation of neutral and
acidic HMO at the following conditions: eluent A, 100 mM-
NaOH; eluent B, 100 mM-NaOH and 250 mM-sodium acetate.
The elution programme started with 3 ml of buffer A followed
by a gradient of up to 100 % buffer B in 30 min and a re-equi-
libration volume of 5 ml buffer A. The flow-rate of 1·0 ml/min
was used and 25ml of 1 or 4 mg/ml solutions were injected.
Molar response factors were determined by injecting three to
six times equimolar amounts of each oligosaccharide as
described previously(18).
Fast atom bombardment-MS
Oligosaccharides (50–100mg) were dissolved in 500ml of
pyridine–acetic anhydride (1:1, v/v). The mixture was stirred
at room temperature overnight. Then the solvent was evapor-
ated under N2 and the residue was used for mass spectro-
metric analysis without further purification. The FAB-MS
analysis was carried out on a VG-ZAB-T four-sector instrument
(Fisons Instruments, Manchester, UK); caesium was used for
atom bombardment(16). The applied acceleration voltage was
8 kV. Thioglycerol–m-nitrobenzylalcohol (1:1, v/v) was used
as matrix to which 1ml of a homogeneous sample solution
in chloroform–methanol (1:1, v/v) was added. For spectra
recording, positive ions (FAB þ ) were detected on the
second photomultiplier point detector. The spectra were run
in a mass range from 100 to 3000 atom mass units with a
scan rate of 8 s per decay and up to ten scans were
accumulated.
Determination of 13C enrichment by isotope ratio-MS
13C enrichment was determined as d 13CPDB measured in
duplicate in whole milk, milk carbohydrates, total urine and
urinary carbohydrate fractions by IR-MS (Isoprime; Isoprime
Limited, formerly: GV Instruments; Manchester, UK) after
total combustion at 10208C (EuroEA, Eurovector, Milan,
Italy)(16). Breath samples were analysed in a BreathMat IRMS
Microgas IRMS, Isoprime Limited). 13C elimination rates were
then quantified as described in the following subsection.
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13C analysis by isotope ratio-MS
The 13C content of a sample is expressed as delta value (d 13CPDB)
(‰) which is the relative difference between the 13C:12C ratio
of a sample (Sa) and the international Pee Dee Belemnite
(PDB) standard with a (13C:12C)PDB ratio of 0·0112372,
d 13CPDB ð‰Þ ¼ ð13RSa 213RPDBÞ=ð13RPDBÞ £ 1000
where 13RSa ¼ (13C/12C)Sa is the isotope ratio of the unknown
sample and PDB is Pee Dee Belemnite.
Data evaluation was performed with MassLynx inorganic
version 4 software (GV Instruments) taking into account
the 17O-content of the sample and the blank correction for the
carbon of the tin cups(16). For an easier comparison of the data,
the results were expressed as Dd 13CPDB (corrected for the
13C:12C ratio at baseline). The accepted standard deviation was
,0·2‰ for total urine and isolated carbohydrates and ,0·7‰
for totalmilk. The accepted deviation for breath sample analyses
was ,0·3‰.
Calculation of the cumulative 13C-enrichment in milk
and urine
To determine the 13C-enrichment in milk and urine, total
organic carbon (TOC) and 13C-content (at %) for each
sample were measured. Then, the excreted amounts of
13C were calculated, taking into account the baseline 13C
values and the 13C-bolus given.
Using this 13C-at%sa and the TOC of a sample, the absolute
amount of 13C of each sample (Sa) was then calculated as follows:
13Csa ðgÞ ¼ TOCsa ðgÞ £
13C  at%sa
100
;
where at % is atom %.
Calculation of the cumulative 13C exhalation
The percentage recovery of the ingested 13C amount in breath
(13Ccum) was calculated using the equation shown in the pre-
vious subsection. Thereby, the exhaled amount of 13C is
defined as
13Cexcreted ðmol=kgÞ ¼ Dd 13Ccum ð‰ £ hÞ £13 RPDB £ CO2
2 P ðmmol=kg £ hÞ;
with Dd 13Ccum being the cumulative
13C exhalation.
Determination of galactose and lactose content
Gal and lactose contents of milk and urine were photometri-
cally determined using a colorimetric kit from Boehringer
Mannheim (Mannheim, Germany).
Calculation of ingested milk volumes and respective
amounts of human milk oligosaccharide
To determine the amount of milk ingested by the infants, the
milk volume was determined by weighing the infants on
a digital electronic balance before and after each nursing.
Oligosaccharides were quantified by HPAEC-PAD analysis.
Peak areas of lacto-N-tetraose (LNT) and lacto-N-fucopentaose
II (LNFP II) were then calculated as percentage of the total
amount of oligosaccharides applied, corrected by the molar
response of the amperometric detector(18).
Results
13C-enrichment of whole milk and 13CO2 exhalation
In all milk samples, there was an immediate increase in
13C-enrichment of whole milk in the first hours after the oral
13C-Gal bolus was given to the mothers followed by a
second smaller 13C-peak in six out of ten milk samples from
the next morning (Fig. 1). To get an indication of how much
Gal was metabolised for energy production, 13C-enrichment
of breath was determined by analysing 13CO2. Exhalation
over 36 h compared to the 13C:12C ratio in whole milk resulted
in a similar course although with a much higher enrichment in
most samples (Fig. 1).
HPAEC-PAD analysis of the neutral and acidic fractions after
Sephadex G25 gel filtration chromatography revealed a rather
complex mixture of carbohydrates which were then character-
ised by FAB-MS. As an example, the composition of the major
acidic and neutral HMO is given in Table 1. The molecular
weight of these oligosaccharides varied between about 500
and 2500 Da.
Determination of the 13C-enrichment of the infants’ urine
The 13C:12C ratio of urine fractions collected over 36 h after the
Gal bolus was given to their mothers is shown in Fig. 1. The
13C-enrichment follows about the same pattern as in whole
milk. Also, the first 13C-appearance in most urine fractions is
delayed as compared to the corresponding milk fraction.
To ensure that the higher 13C:12C ratio is not due to the
excretion of free 13C-Gal, we determined the total Gal
excretion by enzymatic methods. The data which are exempli-
fied for one infant in Fig. 2 revealed that the excretion of free
Gal was only high in the first sample after the Gal bolus was
given to the mother, and returned to baseline afterwards. In
contrast to the total Gal excretion, the 13C-enrichments in
the same urine fractions reached their maximum value 10–
11 h (fraction 4) after the Gal bolus was given to the mother.
To characterise 13C-enriched carbohydrates, urine fractions
were subjected to Sephadex gel filtration to obtain com-
ponents of different molecular sizes and to separate monosac-
charides and lactose from oligosaccharides. These fractions
were further characterised by HPAEC-PAD, IR-MS and
FAB-MS. The major components in these fractions are
shown in Table 2. Not only small oligosaccharides such as
the lactose derivatives FucLac and Fuc2Lac were detected
but also LNT, one of the main core structures in HMO
(Table 2). Moreover, the mono-, di- and trifucosylated deriva-
tives of LNT, lacto-N-hexaose, lacto-N-octaoses and lacto-N-
decaose could be found. Also, besides neutral components,
N-acetylneuraminyl-lactose (NeuAcLac), the major acidic
component in HMO and the sialylated derivative of LNT,
Human milk oligosaccharides in infants’ urine 959
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Fig. 1. 13C-enrichment of whole milk (–V–) and infants’ urine (–S–) and 13CO2 exhalation by the mothers (–K–) during the first 36 h after the oral intake of a
galactose (Gal) bolus consisting of 4 g 13C-Gal þ 23 g Gal by the mothers. The d 13CPDB (‰) values of each sample are corrected over the baseline values of
each respective sample obtained at time point 0, immediately before the Gal intake. The bolus was taken after breakfast which varied between 08.00 and
09.30 hours.
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N-acetylneuraminyl-lacto-N-tetraose, were also present. In
addition, fucosyl-lactosamin and fucosyl-lacto-N-triose were
identified, with glucose split off from the reducing end of
the oligosaccharides (Table 2).
Quantification of lacto-N-tetraose and lacto-N-
fucopentaose II in milk and in the infants’ urine
As the milk volume ingested by an infant per suckling was
known, we were able to determine in one infant the total
amount of LNT and LNFP II taken up with each suckling
(Table 3). The total intake of both components varies between
46 and 98 mg for LNT and between 63 and 157 mg for LNFP II
per suckling. The determination of the same components in
the urine fraction allowed us to quantify the total urinary
excretion of these HMO (Table 4).
Discussion
There is increasing evidence, supported in recent years by
animal studies, that HMO have specific beneficial effects
on the infant(14,15). Concomitantly with these observations,
progress in biotechnology today allows to produce at least
some of the major milk oligosaccharides to be potentially
added to infant formula at reasonable costs. However, to be
able to decide which compound should be added, and in
which concentrations or combinations, studies are needed
regarding absorption, metabolism and functions in the infants.
Previously, we have shown that a major part of a 13C-Gal
bolus orally given to lactating mothers was immediately trans-
ported to the lactating gland and is directly incorporated into
HMO(16). These results have been confirmed in the present
study. Thus, using stable isotopes, an in vivo 13C-labelling of
HMO can be achieved to address important questions with
regard to their metabolic fate.
Here, we show that in urine of ten infants, HMO are found
in all samples collected within 36 h after a 13C-Gal bolus was
given to their mothers. The infants’ urinary oligosaccharides
can only be derived from milk as the biosynthesis of
HMO occurs exclusively in the lactating mammary gland.
Also, the excretion of intact HMO in the present study with
Table 1. Fast atom bombardment-MS of the major neutral and
acidic human milk oligosaccharides from one mother in fractions after
Sephadex 25 chromatography
Nominal m/z values of
detected molecular
ions
[M þ H]þ [M þ Na]þ Oligosaccharide Composition
Neutral peracetylated oligosaccharides
701 Lac Hex2
931 FucLac FucHex2
1254 1276 LNT Hex3HexNAc
1484 1506 Fuc1LNT FucHex3HexNAc
1714 – Fuc2LNT Fuc2Hex3HexNAc
1829 – LNH Hex4HexNAc2
2059 2081 Fuc1LNH FucHex4HexNAc2
2289 2311 Fuc2LNH Fuc2Hex4HexNAc2
2634 2656 Fuc1LNO FucHex5HexNAc3
2864 2886 Fuc2LNO Fuc2Hex5HexNAc3
3094 3116 Fuc3LNO Fuc3Hex5HexNAc3
3209 3231 Fuc1LND FucHex6HexNAc4
Acidic peracetylated oligosaccharides
1036 1058 NeuAcLac
(Lacton)
NeuAcHex2
1096 1118 NeuAcLac NeuAcHex2
1671 – NeuAcLNT NeuAcHex3HexNAc
2028 – NeuAc2LNT
(Lacton)
NeuAc2Hex3HexNAc
2246 – NeuAcLNH NeuAcHex4HexNAc2
2476 – NeuAcFuc1LNH NeuAcFucHex4HexNAc2
Lac, lactose; Hex, hexose; NAc, N-acetyl; FucLac, fucosyl-lactose; LNT, lacto-N-
tetraose; FucLNT, fucosyl-lacto-N-tetraose; FucLNH, fucosyl-lacto-N-hexaose;
NeuAcLac, N-acetylneuraminyl-lactose; NeuAcLNT, N-acetylneuraminyl-lacto-N-
tetraose.
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Fig. 2. Excretion of free urinary galactose ( ) and 13C-enrichment ( ) in
fractions of an infant’s urine over 24 h.
Table 2. Fast atom bombardment-MS of neutral and acidic oligosac-
charides from an infant’s urine
Nominal m/z values of
detected molecular ions
[M þ H]þ [M þ Na]þ Oligosaccharide Composition
Neutral peracetylated oligosaccharides
679 701 Lac Hex2
908 – FucLacNAc FucHexHexNAc
909 931 FucLac FucHex2
1139 – Fuc2Lac Fuc2Hex2
1196 1218 Fuc1LNTri FucHex2HexNAc
1254 1276 LNT Hex3HexNAc
1484 1506 Fuc1LNT FucHex3HexNAc
1714 1736 Fuc2LNT Fuc2Hex3HexNAc
1853 Hex6
2289 2311 Fuc2LNH Fuc2Hex4HexNAc2
2519 2541 Fuc3LNH Fuc3Hex4HexNAc2
Native acidic oligosaccharides
[M 2 H]2
632 – NeuAcLac NeuAcHex2
997 – NeuAcLNT NeuAcHex3HexNAc
1347 – NeuAcFuc1
HexNAcLNT
NeuAcFucHex3HexNAc2
Lac, lactose; Hex, hexose; FucLacNAc, fucosyl-lactosamin; FucLac, fucosyl-
lactose; Fuc1LNTri, fucosyl-lacto-N-triose; LNT, lacto-N-tetraose; NAc, N-acetyl;
FucLNT, fucosyl-lacto-N-tetraose; LNH, lacto-N-hexaose; FucLNH, fucosyl-lacto-
N-hexaose; FucLNO, fucosyl-lacto-N-octaose; FucLND, fucosyl-lacto-N-decaose;
NeuAcLac, N-acetylneuraminyl-lactose; NeuAcLNT, N-acetylneuraminyl-lacto-
N-tetraose; NeuAcFucLNH, N-acetylneuraminyl-fucosyl-lacto-N-hexaose.
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term infants at 3–6 months postpartum verifies our earlier data
in preterm infants showing very similar data without using
stable isotopes(19).
Besides intact HMO, we also detected cleavage products in
which not, as expected, the terminal Gal but the glucose
moiety on the reducing end had been split off. At the
moment, no plausible explanation can be given for such
an unusual metabolic degradation step. There is only one
congress contribution from Lundblad’s group on the renal
excretion of oligosaccharides in a few preterm and full-term
infants using mass spectrometric methods for analysis(20).
The authors found that small ‘typical milk oligosaccharides’
were excreted by human milk-fed infants. Most of the ana-
lysed urine samples contained 20- and 3-FucLac as well as
Fuc2Lac. They could not detect these components in the
urine of non-breastfed infants. A further comparison with
our data regarding complex oligosaccharides such as LNT
and fucosylated and/or sialylated derivatives as well as NeuA-
cLac is not feasible, since Lundblad and co-workers did not
report the analysis of such components.
There are two possible explanations for the occurrence of
‘modified’ oligosaccharides in urine; either they may originate
from human milk itself or they are synthesised endogenously
from smaller precursors. Although there is no evidence from
in vivo studies yet, these modifications may derive from bac-
terial activity within the gut. Also, if such HMO modifications
occur within the colon, the underlying mechanism of the suc-
ceeding absorptive process needs to be demonstrated as well.
In the present study, we also determined the amount of
HMO an exclusively breastfed infant may receive with each
suckling. We showed that the intake of individual oligosac-
charides by the infant ranges from 50 to 150 mg per suckling.
This large amount of oligosaccharides which ‘rinse’ the whole
digestive tract emphasises the potential of anti-adhesive or
cellular effects shown for individual carbohydrates in many
in vitro studies(2,9,11,21–24). However, to exert systemic effects,
HMO must be absorbed and transported in the peripheral
blood to specific cells where they might also be metabolised.
Although HMO are considered to be indigestible(25), we
detected specific components like LNT and LNFP II in the
infants’ urine indicating intestinal absorption. As the renal
excretion was in the range between 1 and 3 mg/d, the actual
intestinal absorption must be much higher, and hence, larger
amounts of these HMO must have been circulating in the
infant’s blood. Therefore, in addition to local functions of
HMO within the gastrointestinal tract, systemic effects such
as the adhesion of leucocytes to endothelial cells or the inter-
action of platelets with neutrophils may be influenced(12,23).
Recently, an impact of HMO on brain glycoconjugate compo-
sition has also been discussed. Carlson & House(26) compared
an intra-peritoneal administration to an intra-gastrical appli-
cation of NeuAc on rat brain composition, and found that
both oral and systemic routes resulted in significantly more
cerebral and cerebellar glycolipid and glycoprotein NeuAc
than did glucose injections. Compared to free NeuAc, orally
given NeuAcLac, the major acidic oligosaccharide in human
milk, was even more effective on brain composition. These
data supported an earlier observation by Witt et al.(27) compar-
ing radiolabelled free NeuAc and NeuAcLac; the authors
showed a preferential incorporation of 14C-NeuAcLac in rat
brain gangliosides. Our data suggest that the absorption of
HMO in breastfed infants supports the possibility that sialic
acid from HMO is utilised as a substrate for the biosynthesis
of components including gangliosides or glycoproteins (e.g.
for the brain).
In conclusion, we have shown that the application of
13C-labelled HMO alleviates investigations regarding the meta-
bolic fate of HMO in human subjects. The intake of HMO by
the infants ranges within several hundred mg per suckling.
Some of these components are excreted as intact oligosacchar-
ides or as slightly modified metabolites within the infants’
urine. Therefore, HMO have the potential for not only local
but also systemic effects. Such effects, however, remain to
be demonstrated in future studies. The enormous biotech-
nological progress in recent years will enable necessary
studies in vivo.
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Table 3. Milk concentration and total intake of lacto-N-tetraose (LNT)
and lacto-N-fucopentaose II (LNFP II) per suckling in one infant
(Mean values and standard deviations from five samples of one day)
Concentration (mg/ml)*
Total intake
through milk (mg)
Volume
(ml)
LNT LNFP II
Suckling Mean SD Mean SD LNT LNFP II
1 97·0 0·77 0·01 1·10 0·03 74·73 106·30
2 126·1 0·78 0·01 1·25 0·04 98·22 157·17
3 58·2 0·79 0·00 1·09 0·01 46·20 63·53
4 97·0 0·77 0·09 1·07 0·11 75·08 103·80
5 97·0 0·57 0·00 0·85 0·01 55·56 82·25
Table 4. Urinary concentration and total excretion of lacto-N-tetraose
(LNT) and lacto-N-fucopentaose II (LNFP II) per suckling in one infant
(Mean values and standard deviations from five samples of one day)
Concentration (mg/ml)
Total excretion
in urine (mg)
Urine
sample
Volume
(ml)
LNT LNFP II
Mean SD Mean SD LNT LNFP II
1 35·0 13·4 0·2 13·1 0·4 0·47 0·46
2 25·0 21·2 0·5 22·6 1·5 0·53 0·56
3 26·3 11·4 0·2 12·4 0·5 0·30 0·33
4 19·7 7·3 0·1 7·0 0·1 0·14 0·14
5 23·2 11·6 0·3 13·3 0·1 0·27 0·31
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